Literature DB >> 9686189

IFN-gamma in human Chagas' disease: protection or pathology?

L M Bahia-Oliveira1, J A Gomes, M O Rocha, M C Moreira, E M Lemos, Z M Luz, M E Pereira, R L Coffman, J C Dias, J R Cançado, G Gazzinelli, R Corrêa-Oliveira.   

Abstract

An apparently paradoxical role for IFN-gamma in human Chagas' disease was observed when studying the pattern of cytokine production by peripheral blood mononuclear cells (PBMC) obtained from two groups of chagasic patients after specific stimulation with Trypanosoma cruzi-derived antigens. The groups studied were 1) patients treated with benznidazole during the acute phase of Trypanosoma cruzi infection and 2) chronically infected untreated patients. In the treated group, higher levels of IFN-gamma were produced by PBMC from individuals cured after treatment when compared to non-cured patients. In contrast, in the chronically infected group (not treated) higher levels of IFN-gamma were produced by PBMC from cardiac patients in comparison with asymptomatic (indeterminate) patients. This apparently paradoxical role for IFN-gamma in human Chagas' disease is discussed in terms of the possibility of a temporal difference in IFN-gamma production during the initial stages of the infection (acute phase) in the presence or absence of chemotherapy. The maintenance of an immune response with high levels of IFN-gamma production during the chronic phase of the infection may favor cure or influence the development of the cardiac form of the disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9686189     DOI: 10.1590/s0100-879x1998000100017

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  27 in total

1.  Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients.

Authors:  Juliana A S Gomes; Lilian M G Bahia-Oliveira; Manoel Otávio C Rocha; Solange C U Busek; Mauro M Teixeira; João Santana Silva; Rodrigo Correa-Oliveira
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  Assessment of CD8(+) T cell differentiation in Trypanosoma cruzi-infected children.

Authors:  María Cecilia Albareda; Gabriela Carina Olivera; Ana María De Rissio; Miriam Postan
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

Review 3.  Immunoregulatory networks in human Chagas disease.

Authors:  W O Dutra; C A S Menezes; L M D Magalhães; K J Gollob
Journal:  Parasite Immunol       Date:  2014-08       Impact factor: 2.280

4.  Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection.

Authors:  Bianca Perdigão Olivieri; Vinícius Cotta-De-Almeida; Tania Araújo-Jorge
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

5.  DNA from protozoan parasites Babesia bovis, Trypanosoma cruzi, and T. brucei is mitogenic for B lymphocytes and stimulates macrophage expression of interleukin-12, tumor necrosis factor alpha, and nitric oxide.

Authors:  L K Shoda; K A Kegerreis; C E Suarez; I Roditi; R S Corral; G M Bertot; J Norimine; W C Brown
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

6.  Modulation of chagasic cardiomyopathy by interleukin-4: dissociation between inflammation and tissue parasitism.

Authors:  M B Soares; K N Silva-Mota; R S Lima; M C Bellintani; L Pontes-de-Carvalho; R Ribeiro-dos-Santos
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

7.  T-Cell Immunophenotyping and Cytokine Production Analysis in Patients with Chagas Disease 4 Years after Benznidazole Treatment.

Authors:  Mauricio Llaguno; Marcos Vinicius da Silva; Lara Rocha Batista; Djalma Alexandre Alves da Silva; Rodrigo Cunha de Sousa; Luiz Antonio Pertili Rodrigues de Resende; Valdo Jose Dias da Silva; Eliane Lages-Silva; Carlo José Freire Oliveira; Juliana Reis Machado; Denise Bertulucci Rocha Rodrigues; Dalmo Correia; Virmondes Rodrigues
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

8.  Cellular immune response from Chagasic patients to CRA or FRA recombinant antigens of Trypanosoma cruzi.

Authors:  Virginia M B Lorena; Alinne F A Verçosa; Raquel C A Machado; Lucas Moitinho-Silva; Maria G A Cavalcanti; Edimilson D Silva; Antonio G P Ferreira; Rodrigo Correa-Oliveira; Valéria R A Pereira; Yara M Gomes
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

9.  Familial analysis of seropositivity to Trypanosoma cruzi and of clinical forms of Chagas disease.

Authors:  Roseane L Silva-Grecco; Marly A S Balarin; Dalmo Correia; Aluízio Prata; Virmondes Rodrigues
Journal:  Am J Trop Med Hyg       Date:  2010-01       Impact factor: 2.345

10.  Increase in the expression of CD4 + CD25+ lymphocytic T cells in the indeterminate clinical form of human Chagas disease after stimulation with recombinant antigens of Trypanosoma cruzi.

Authors:  Suellen Carvalho de Moura Braz; Adriene Siqueira de Melo; Maria da Glória Aureliano de Melo Cavalcanti; Sílvia Marinho Martins; Wilson de Oliveira; Edimilson Domingos da Silva; Antonio Gomes Pinto Ferreira; Virginia Maria Barros de Lorena; Yara de Miranda Gomes
Journal:  J Clin Immunol       Date:  2014-09-10       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.